日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma

rucaparib 和 nivolumab 治疗平滑肌肉瘤患者的 II 期研究

Sujana Movva ,Kenneth Seier ,Martina Bradic ,Karmelina Charalambous ,Evan Rosenbaum ,Ciara M Kelly ,Seth M Cohen ,Martee L Hensley ,Viswatej Avutu ,Lauren B Banks ,Jason E Chan ,Ping Chi ,Sandra D'Angelo ,Mark A Dickson ,Mrinal M Gounder ,Mary L Keohan ,Robert G Maki ,Angela Green ,Vicky Makker ,Maria M Rubinstein ,Sara Saunds ,Jae-Mun Cho ,Robert A Lefkowitz ,Joseph Erinjeri ,Li-Xuan Qin ,Ronak Shah ,Phillip Wong ,William Tap

Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors

回顾性分析采用聚(ADP-核糖)聚合酶抑制剂治疗的BRCA突变子宫肉瘤

Rao, Mara; Merrill, Madeline; Troxel, Megan; Chiang, Sarah; Momeni-Boroujeni, Amir; Hensley, Martee L; Schram, Alison M

Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate

使用抗FOLR1抗体-药物偶联物治疗晚期卵巢癌患者的预后

Johannet, Paul; Flint, Matthew; Chui, M Herman; Konner, Jason; Friedman, Claire; Green, Angela K; Guo, Robin; Hensley, Martee L; Kyi, Chrisann; Liu, Ying; Makker, Vicky; Rubinstein, Maria; Sabbatini, Paul; Tew, William P; Foote, Michael B; Weigelt, Britta; Aghajanian, Carol; Grisham, Rachel N; O'Cearbhaill, Roisin E

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses

纳武利尤单抗治疗错配修复缺陷或高突变妇科癌症:一项包含生物标志物分析的 2 期试验

Friedman, Claire F; Manning-Geist, Beryl L; Zhou, Qin; Soumerai, Tara; Holland, Aliya; Da Cruz Paula, Arnaud; Green, Hunter; Ozsoy, Melih Arda; Iasonos, Alexia; Hollmann, Travis; Leitao, Mario M Jr; Mueller, Jennifer J; Makker, Vicky; Tew, William P; O'Cearbhaill, Roisin E; Liu, Ying L; Rubinstein, Maria M; Troso-Sandoval, Tiffany; Lichtman, Stuart M; Schram, Alison; Kyi, Chrisann; Grisham, Rachel N; Causa Andrieu, Pamela; Wherry, E John; Aghajanian, Carol; Weigelt, Britta; Hensley, Martee L; Zamarin, Dmitriy

Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma

开发软组织和子宫平滑肌肉瘤的新型基因组风险分层模型

Dermawan, Josephine K; Chiang, Sarah; Singer, Samuel; Jadeja, Bhumika; Hensley, Martee L; Tap, William D; Movva, Sujana; Maki, Robert G; Antonescu, Cristina R

The Impact of Li-Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations

Li-Fraumeni 和生殖系视网膜母细胞瘤突变对平滑肌肉瘤发生、预后和基因检测建议的影响

Dermawan, Josephine K; Abramson, David H; Chiang, Sarah; Hensley, Martee L; Tap, William D; Movva, Sujana; Maki, Robert G; Mandelker, Diana; Antonescu, Cristina R

Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma

针对肉瘤患者的乐伐替尼和帕博利珠单抗组织学特异性临床试验

Movva, Sujana; Seier, Kenneth; Avutu, Viswatej; Banks, Lauren B; Chan, Jason; Chi, Ping; Dickson, Mark A; Gounder, Mrinal M; Kelly, Ciara M; Keohan, Mary L; Maki, Robert; Rosenbaum, Evan; Salcito, Tiffany; Rodriguez, Kaithleen; Dempsey, Rebecca; Meyers, Paul A; Cohen, Seth M; Hensley, Martee L; Konner, Jason A; Schram, Alison M; Lefkowitz, Robert A; Erinjeri, Joseph P; Qin, Li-Xuan; Tap, William D; D'Angelo, Sandra P

High-Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations

具有肌源性分化且携带热点PDGFRB突变的高级别肉瘤

Dermawan, Josephine K; Chiang, Sarah; Hensley, Martee L; Tap, William D; Antonescu, Cristina R

Molecular-Based Immunohistochemical Algorithm for Uterine Leiomyosarcoma Diagnosis

基于分子生物学的子宫平滑肌肉瘤免疫组织化学诊断算法

Momeni-Boroujeni, Amir; Yousefi, Elham; Balakrishnan, Ridin; Riviere, Stephanie; Kertowidjojo, Elizabeth; Hensley, Martee L; Ladanyi, Marc; Ellenson, Lora H; Chiang, Sarah

Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination

采用多价疫苗联合贝伐珠单抗治疗复发性卵巢癌患者的长期疗效

Kahn, Ryan M; Ragupathi, Govind; Zhou, Qin C; Iasonos, Alexia; Kravetz, Sara; Hensley, Martee L; Konner, Jason A; Makker, Vicky; Tew, William P; Aghajanian, Carol; Sabbatini, Paul J; O'Cearbhaill, Roisin E